InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq
October 15, 2024 16:05 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that its Series B Preferred Stock investors, Ampersand...
Logo.png
Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility
November 04, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
Clinical Data Highlights the Utility of ThyGeNEXT® and ThyraMIR® PARSIPPANY, NJ, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Interpace Group (NASDAQ: IDXG) Interpace Diagnostics announced today the...
Logo.png
Interpace Named to ‘Most Admired Companies’ List
October 15, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The...
Logo.png
Interpace to Present at The Ladenburg Thalmann 2019 Healthcare Conference
September 18, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming...
Logo.png
Interpace to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright
September 06, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming 21st...
Logo.png
Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update
August 13, 2019 08:15 ET | Interpace Diagnostics Group, Inc.
Second Quarter Revenue Grew 14% Over the Prior Year and 19% Year to Date Over the Prior Year Acquired Growing BioPharma Services Business Net Revenue Guidance Increased Conference Call and...
IDXG Logo.jpg
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019
May 06, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, May 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc., (IDXG:NASDAQ) announced today that it will report its first quarter 2019 financial results after the close of...
IDXG Logo.jpg
Interpace Diagnostics Announces Further Expansion of Thyroid Business
January 22, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
Interpace Only Provider Validated to Offer MDx Tests on Three Distinct Platforms PARSIPPANY, NJ, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that it...
IDXG Logo.jpg
Interpace Announces Notice of Allowance from U.S. Patent and Trademark Office Covering BarreGEN®
December 17, 2018 06:50 ET | Interpace Diagnostics Group, Inc.
BarreGEN® is Interpace’s Lead Molecular Diagnostic Pipeline Product for Barrett’s Esophagus Parsippany, NJ, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace”)...
IDXG Logo.jpg
Interpace Diagnostics CEO Provides Corporate Update
October 10, 2018 08:30 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) is pleased to provide a corporate update to shareholders on current business activities from its Chief...